Corporate Profile
Alectos Therapeutics is a private pharmaceutical company dedicated to the discovery and preclinical development of novel small-molecule therapeutics for neurological diseases. Alectos focuses on identifying and developing innovative disease-modifying strategies to address complex neurological conditions for which there are no effective treatments, including Alzheimer’s disease, Parkinson’s disease, and acute ischemic stroke.
The Alectos pipeline is directed towards the development of new agents to treat patients living with neurological disorders. Our glucocerebrosidase 2 (GBA2) program represents a disease-modifying strategy to correct lysosomal dysfunction in neurodegenerative diseases, including Parkinson’s disease, Niemann-Pick type C disease, and Batten disease. Our O-GlcNAcase (OGA) program focuses on the development of neuroprotective therapies to counteract the effects of cellular stress in the brain. Alectos partnered with Merck to pioneer the development of the first OGA inhibitor to enter clinical studies. This program has now returned to Alectos, and we are applying our broad intellectual property and deep knowledge in this space to advance our novel OGA inhibitors as disease-modifying treatments for neurodegenerative diseases including AD/PD, as well as for acute conditions such as ischemic stroke and traumatic brain injury. We welcome partnership inquiries regarding our OGA and GBA2 programs.
